Single TearCare® treatment enhances vision and eases dry eye symptoms, study finds

Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced that a new study titled, Impact of TearCare on Reading Speed in Patients with Dry Eye Disease, has been published in the peer-reviewed journal Clinical Ophthalmology.

Key study findings reported in the study manuscript include:

• 52% of participants (N = 32) had a clinically significant improvement in reading speed after therapy with TearCare, defined as a greater than 10 words per minute increase in their International Reading Speed Texts (“IReST”) score. Improvements on the IReST and the Minnesota Low Vision Reading Test (“MNREAD”) reached statistical significance (p=0.012 and p=0.028, respectively).
• Ocular Surface Disease Index (“OSDI”) scores and National Eye Institute Visual Function Questionnaire 25 (“NEI-VFQ-25”) scores which measure symptoms and vision-related quality of life were both significantly improved after TearCare treatment (both p<0.001).
• Significant improvements in all dry eye disease (“DED”) sign metrics (p<.0.001), including tear break-up time, meibomian gland secretion score, and corneal fluorescein staining.

“A large portion of the patients I see in my practice experience significant issues from their dry eye disease. The disease can impact their quality of life and when it goes untreated patients can have reduced visual function,” said Preeya K. Gupta, MD, senior author and Director of Triangle Eye Consultants. “We are very pleased that this study demonstrated how a single in-office intervention with TearCare addressed the visual dysfunction associated with dry eye disease.”

This prospective single-center study evaluated the impact of TearCare treatment on clinical, vision-related quality of life, and functional visual outcome metrics in patients with meibomian gland disease (“MGD”) associated DED. The findings suggest patients who underwent a TearCare treatment exhibited improvements in vision-related quality of life and improved reading speeds after a single treatment. The study suggests that this interventional dry eye treatment should be considered and utilized to reduce the disease burden of MGD associated DED.